Objective To observe the efficacy and safety of allisartan in treatment of mild to moderate elder-ly essential hypertension.Methods The trial enrolled 60 subjects with mild to moderate essential hypertension.Sub-jects were randomized divided into allisartan 80 mg group,allisartan 160 mg group and irbesartan 150 mg group by 1∶1∶1,and all subjects were treated for 12 weeks.Results Compared with baseline,diastolic blood pressure (DBP) and systolic blood pressure(SBP)of the three groups were reduced significantly after 12 weeks.The blood pressure of 80 mg group,160 mg group and irbesartan 150 mg group respectively reduced 13.8 /7.9 mmHg,14.5 /7.3 mm Hg and 15.3 /8.8 mmHg.There were no differences in the decrease of blood pressure among three groups.The rate of drug related adverse event was similar among three groups.Conclusion Allisartan can reduce systolic and diastolic blood pressure significantly and safety in elderly hypertension.%目的观察阿利沙坦酯治疗老年轻中度原发性高血压的有效性及安全性。方法选取老年轻中度原发性高血压患者60例，男性36例，女性24例，按1∶1∶1的比例随机分为3组，阿利沙坦酯80 mg 组20例、阿利沙坦酯160 mg 组20例、厄贝沙坦150 mg 组20例，入选患者治疗12周。结果治疗12周后三组患者收缩压及舒张水平较基线均明显下降，阿利沙坦酯80 mg 组、阿利沙坦酯160 mg 组、厄贝沙坦150 mg 组收缩压／舒张压分别降低13．8／7．9 mm Hg、14．5／7．3 mm Hg 及15．3／8．8 mm Hg，各血压组内不同时间点差异有统计学意义（P ＜0．05），各血压组间差异无统计学意义（P ＞0．05）。结论阿利沙坦酯应用于老年轻中度原发性高血压安全有效。
展开▼
